{
  "abstract": "Psoriasis is often associated with obesity and type 2 diabetes mellitus (T2DM) due to a common low-grade chronic inflammatory mechanism amplified by metabolic dysfunction. Biologics have revolutionized psoriasis treatment, but patients with obesity show reduced responses and higher discontinuation rates. Glucagon-like peptide-1 receptor agonists—such as semaglutide—may enhance the efficacy of psoriasis care; however, data are limited in this context. We presented a retrospective analysis of our single-center real-world experience with 33 obese patients (24 men and 9 women) affected by mild (n = 19, 57.6%) or moderate (n = 14, 42.4%) psoriasis and treated with semaglutide over 18 months. Adherence to the semaglutide prescription was 94% (range 88–99%), with most patients (54.5%) having a last recorded dose of 1.0 mg. A significant mean reduction of 4.25 points in the PASI score (from 9.31 ± 1.54 to 5.05 ± 0.88; p < 0.001) was reported, followed by a mean decrease of 4.15 kg/m2 in BMI (from 32.53 ± 1.92 to 28.38 ± 1.59 kg/m2; p < 0.001) and significant improvements in all metabolic parameters. In addition, there was a significant decrease in inflammatory markers (CRP decreased from 5.47 ± 1.69 to 2.69 ± 0.94 mg/L, and ESR from 17.76 ± 4.22 to 11.64 ± 2.83 mm/h). More than fifty-seven percent (57.6%) of patients experienced mild and transitory gastrointestinal reactions, but no cases of discontinuation or cutaneous reaction occurred. Data provide additional insights into the role of semaglutide in patients with mild-to-moderate psoriasis. Large-scale, multicenter studies are needed to validate long-term results.",
  "abstract_shown": true,
  "affiliations": [
    "UOC DERMATOLOGIA ‘Daniele Innocenzi’-ASL LATINA Sapienza Università di Roma-Polo Pontino, Corso della Repubblica, 79, 04100 Latina, Italy"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 2,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Ilaria Proietti"
    },
    {
      "affs": [
        0
      ],
      "name": "Concetta Potenza"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/9xzrcq2f61gt9.bib",
  "cited_by": 0,
  "doi": "10.3390/jcm15208015",
  "fulltext_url": null,
  "id": "9xzrcq2f61gt9",
  "issns": [
    "2077-0383"
  ],
  "landing_url": "https://www.mdpi.com/2077-0383/15/20/8015",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2403|Psoriasis: Treatment and Pathogenesis"
    ]
  ],
  "openalex": "W7222410992",
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-16",
  "publisher": "MDPI AG",
  "ris": "https://research.draconitic.com/paper/9xzrcq2f61gt9.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:00Z",
      "native_id": "10.3390/jcm15208015",
      "source": "crossref",
      "url": "https://www.mdpi.com/2077-0383/15/20/8015"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "openalex:2403|Psoriasis: Treatment and Pathogenesis",
      "subfield": "immunology"
    }
  ],
  "title": "Semaglutide in Patients with Obesity and Psoriasis: Insights from an 18-Month Real-World Experience",
  "title_text": "Semaglutide in Patients with Obesity and Psoriasis: Insights from an 18-Month Real-World Experience",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:00Z",
  "url": "https://research.draconitic.com/paper/9xzrcq2f61gt9",
  "venue": "Journal of Clinical Medicine",
  "versions": []
}